Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.

Kubicek GJ, Axelrod RS, Machtay M, Ahn PH, Anne PR, Fogh S, Cognetti D, Myers TJ, Curran WJ Jr, Dicker AP.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1192-7. doi: 10.1016/j.ijrobp.2011.09.023. Epub 2012 Jan 13.

PMID:
22245208
2.

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, Giaccone G.

Clin Cancer Res. 2007 Jun 15;13(12):3642-51.

3.

A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.

Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, Shen R, Korte S, Lisa D, Ganly I, Patel S, Wong RJ, Shaha A, Shah J, Haque S, Katabi N, Pfister DG.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):479-86. doi: 10.1016/j.ijrobp.2013.06.2043.

PMID:
24074921
4.

Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.

Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL.

J Clin Oncol. 2004 Aug 1;22(15):3061-9.

PMID:
15284256
5.
6.

Weekly gemcitabine and cisplatin in combination with radiotherapy in patients with locally advanced head-and-neck cancer: Phase I study.

Viani GA, Afonso SL, Tavares VC, da Silva LG, Stefano EJ.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e231-5. doi: 10.1016/j.ijrobp.2011.02.012. Epub 2011 May 11.

PMID:
21570216
7.

Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.

Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven KE, Swing R, Raben D.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):521-6. doi: 10.1016/j.ijrobp.2009.07.1715. Epub 2010 Feb 3.

PMID:
20133082
8.

Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.

Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):678-84.

PMID:
17293229
9.

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, Fayette J, Mehanna H, El-Hariry I, Compton N, Franklin N, Biswas-Baldwin N, Lau M, Legenne P, Kumar R.

Eur J Cancer. 2013 May;49(7):1609-18. doi: 10.1016/j.ejca.2012.11.023. Epub 2012 Dec 19.

PMID:
23265705
10.

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.

Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr, Eder JP.

Cancer. 2006 Nov 15;107(10):2482-9.

11.

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.

Recchia F, Lalli A, Lombardo M, De Filippis S, Saggio G, Fabbri F, Rosselli M, Capomolla E, Rea S.

Cancer. 2001 Aug 15;92(4):814-21.

PMID:
11550152
12.

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.

J Clin Oncol. 2004 Jun 1;22(11):2108-21.

PMID:
15169797
13.

Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.

Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ.

Am J Clin Oncol. 2008 Feb;31(1):1-5. doi: 10.1097/COC.0b013e31805c142f.

PMID:
18376220
14.

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.

Gynecol Oncol. 2005 Jan;96(1):168-72.

PMID:
15589596
15.

Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.

Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK.

Cancer. 2011 Oct 15;117(20):4671-8. doi: 10.1002/cncr.26084. Epub 2011 Jun 13.

16.

A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.

Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL.

Cancer Chemother Pharmacol. 2010 May;66(1):151-8. doi: 10.1007/s00280-009-1145-z. Epub 2009 Sep 23.

17.

Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.

Bommakanti SV, Dudek AZ, Khatri A, Kirstein MN, Gada PD.

Am J Clin Oncol. 2011 Dec;34(6):597-602. doi: 10.1097/COC.0b013e3181f9441f.

PMID:
21127410
18.

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.

J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. Erratum in: J Clin Oncol. 2006 Feb 20;24(6):1015.

PMID:
16275937
19.

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.

J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.

PMID:
16418495
20.

Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic.

Rütten H, Pop LA, Janssens GO, Takes RP, Knuijt S, Rooijakkers AF, van den Berg M, Merkx MA, van Herpen CM, Kaanders JH.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):923-9. doi: 10.1016/j.ijrobp.2010.07.013. Epub 2010 Nov 20.

PMID:
21095074

Supplemental Content

Support Center